Clinical Evidence: What the Trials Really Show
Understanding the Difference Between Wegovy and Mounjaro UK Weight Loss Mechanisms
The fundamental difference between Wegovy and Mounjaro UK prescriptions lies in their biological mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, working specifically on brain appetite centres to reduce hunger and promote satiety after smaller meals. In contrast, Mounjaro utilises tirzepatide, which acts as a dual agonist targeting both GIP and GLP-1 receptors simultaneously.
This dual mechanism in Mounjaro may provide enhanced metabolic benefits compared to Wegovy's single-pathway approach, though both treatments require administration alongside a reduced-calorie diet and increased physical activity. The difference between Wegovy and Mounjaro UK availability means patients have access to two distinct therapeutic approaches, allowing prescribers to tailor treatment based on individual patient profiles and medical history.
Wegovy vs Mounjaro UK Pricing: Complete Cost Breakdown
Understanding the difference between Wegovy and Mounjaro UK pricing helps patients budget effectively for their weight management journey. Wegovy is available through EverydayMeds with single pens ranging from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenient dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, applied after using discount code FIRST40 at checkout.
For patients requiring consistent dosing, our Stay Steady bundles offer extended supply options, including the Consistency 2.4mg bundle (×2 pens) for £419.99. The Ultimate Stability Trio provides three months of maintenance 2.4mg supply for £649.99, ensuring uninterrupted treatment. All prices include prescriber review, clinical assessment, and next-day cold-chain delivery from our GPhC-registered pharmacy (#9012878).
Clinical Trial Evidence: Wegovy Weight Loss Results in UK Context
When examining the difference between Wegovy and Mounjaro UK clinical evidence, Wegovy's STEP trial programme provides robust data for UK patients. In the pivotal STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo, as published by Wilding et al. in the New England Journal of Medicine, 2021.
The STEP 3 trial demonstrated that Wegovy with intensive behavioural therapy supported approximately 16% average weight loss, whilst STEP 5 showed sustained weight loss of 15.2% at two years. Most significantly for UK patients, the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, highlighting Wegovy's potential beyond weight management when used as prescribed.
How Wegovy Works: The GLP-1 Mechanism Explained
Wegovy functions as a GLP-1 receptor agonist, essentially mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestine when you eat. This mechanism explains part of the difference between Wegovy and Mounjaro UK treatments, as Wegovy specifically targets GLP-1 pathways in the brain's appetite control centres. The medication works by slowing gastric emptying, which helps you feel full sooner and for longer periods after eating smaller portions. Additionally, Wegovy may reduce food cravings and the psychological drive to eat, particularly foods high in fat and sugar. This prescription-only medicine must be used alongside lifestyle modifications, as the combination of medication, reduced-calorie diet, and increased physical activity produces optimal results shown in clinical trials.
EverydayMeds Ordering Process: From Assessment to Delivery
Understanding the difference between Wegovy and Mounjaro UK accessibility, EverydayMeds streamlines the prescription process for both treatments through our comprehensive three-step system. Your journey begins with a three-minute online clinical assessment covering medical history, current medications, weight management goals, and any contraindications that might affect treatment suitability. Our qualified prescribers then review your assessment within three working days (or 24 hours with express service), ensuring appropriate clinical oversight for this prescription-only medicine. Once approved, your Wegovy is dispatched via next-day delivery using temperature-controlled packaging that maintains the required 2-8°C cold chain, ensuring medication integrity upon arrival. Our GPhC-registered pharmacy (#9012878) maintains strict quality standards throughout this process, with tracking provided so you can monitor your delivery progress.
Storage Requirements: Wegovy vs Mounjaro Practical Considerations
A key practical difference between Wegovy and Mounjaro UK prescriptions involves storage requirements and travel convenience. Wegovy must be stored in the refrigerator at 2-8°C before first use but offers superior flexibility once removed, remaining stable at room temperature below 30°C for up to six weeks. This compares favourably to Mounjaro's 21-day room temperature stability, making Wegovy more suitable for extended travel or situations where refrigeration access is limited. The Wegovy FlexTouch pen delivery system requires proper dose escalation starting at 0.25mg for weeks 1-4, progressing through 0.5mg, 1mg, 1.7mg, and finally reaching the 2.4mg maintenance dose by week 17. Each pen contains multiple doses and features clear dosing windows and audible click confirmations to ensure accurate administration throughout your treatment journey.
Evidence-Based Weight Loss Results: UK Patient Considerations
When evaluating the difference between Wegovy and Mounjaro UK outcomes, UK-specific factors influence treatment success beyond clinical trial data. British dietary patterns, NHS weight management pathway integration, and NICE TA875 recommendations all impact real-world effectiveness for UK patients. Wegovy's proven track record in diverse populations, including the significant representation of European patients in STEP trials, provides confidence for UK prescribers and patients.
The sustained weight loss demonstrated in STEP 5, where patients maintained approximately 15.2% weight reduction at two years, particularly relevant for UK patients seeking long-term weight management solutions. However, it's crucial to understand that the STEP 1 extension study showed patients regained approximately two-thirds of lost weight within one year of stopping treatment, emphasising that weight management represents a long-term commitment rather than a short-term intervention.
Professional Clinical Support: Expert Guidance for Your Journey
The difference between Wegovy and Mounjaro UK prescribing requires expert clinical judgement to determine the most appropriate treatment for individual patients. Our qualified prescribers evaluate factors including BMI, weight-related comorbidities, previous weight loss attempts, and potential drug interactions before recommending either treatment. Both medications are subject to MHRA additional monitoring, indicated by the Black Triangle (▼) symbol, ensuring ongoing safety surveillance for UK patients. EverydayMeds provides comprehensive clinical support throughout your treatment journey, from initial assessment through dose escalation and maintenance phases. Our team monitors treatment progress, manages any side effects, and ensures optimal therapeutic outcomes while maintaining full compliance with MHRA licensing requirements for both Wegovy and Mounjaro prescriptions. Start your clinically-supervised weight management journey today using code FIRST40 for new customers or DOSE25 for returning patients, with next-day delivery ensuring prompt treatment initiation once prescribed.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
